Longitudinal investigation of permeability and distribution of macromolecules in mouse malignant transformation using PET

Clinical Cancer Research

Volumn 17, Issue 3, 2011, Pages 550-559

  Rygh, Cecilie B ^a,b,c   Qin, Shengping ^d   Seo, Jai W ^d   Mahakian, Lisa M ^d   Zhang, Hua ^d   Adamson, Roger ^a   Chen, Jane Q ^a   Borowsky, Alexander D ^a   Cardiff, Robert D ^a   Reed, Rolf K ^b   Curry, Fitz Roy E ^a,d   Ferrara, Katherine W ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BOVINE SERUM ALBUMIN; COPPER 64; LIPOSOME; NANOCARRIER; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG HALF LIFE; EARLY CANCER; EXTRAVASATION; INTRADUCTAL CARCINOMA; LONGITUDINAL STUDY; MACROMOLECULE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PERMEABILITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; DISEASE PROGRESSION; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; SERUM ALBUMIN;

EID: 79551704041     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2049     Document Type: Article

References (46)

1. Damonte P, Hodgson JG, Chen JQ, Young LJ, Cardiff RD, Borowsky AD. Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res 2008;10:R50.
2. Maglione JE, McGoldrick ET, Young LJ, Namba R, Gregg JP, Liu L, et al. Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther 2004;3:941-53. (Pubitemid 39199589)
3. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298-305. (Pubitemid 33091625)
4. Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR. Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. J Mammary Gland Biol Neoplasia 2006; 11:137-49. (Pubitemid 46111261)
5. Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, et al. In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A 2004;101:11438-43.
6. Adamson RH, Lenz JF, Zhang X, Adamson GN, Weinbaum S, Curry FE. Oncotic pressures opposing filtration across non-fenestrated rat microvessels. J Physiol 2004;557:889-907. (Pubitemid 38961624)
7. Curry FR, Rygh CB, Karlsen T, Wiig H, Adamson RH, Clark JF, et al. Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume. J Physiol 2010;588:325-39.
8. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83.
9. D'Souza GG, Weissig V. Subcellular targeting: a new frontier for drug-loaded pharmaceutical nanocarriers and the concept of the magic bullet. Expert Opin Drug Deliv 2009;6:1135-48.
10. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008;97:4696-740.
11. Ferrara KW, Borden MA, Zhang H. Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res 2009;42:881-92.
12. Allen TM, Austin GA, Chonn A, Lin L, Lee KC. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1991;1061:56-64.
13. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235-7. (Pubitemid 20233874)
14. Jain RK. Tumor physiology and antibody delivery. Front Radiat Ther Oncol 1990;24:32-46; discussion 64-8.
15. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337-50. (Pubitemid 37164040)
16. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2003;8:259-66. (Pubitemid 36293499)
17. Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO): a new endothelial cell permeability organelle. J Histochem Cytochem 2001;49:419-31. (Pubitemid 32295163)
18. Kohn S, Nagy JA, Dvorak HF, Dvorak AM. Pathways of macromolecular tracer transport across venules and small veins-structural basis for the hyperpermeability of tumor blood vessels. Labo Investigation 1992;67:596-607.
19. Nagy JA, Benjamin L, Zeng HY, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008;11:109-19.
20. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262-71.
21. Michel CC, Curry FE. Microvascular permeability. Physiol Rev 1999;79:703-61. (Pubitemid 29330172)
22. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335-44. (Pubitemid 43338213)
23. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991;174:1275-8.
24. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84. (Pubitemid 30122932)
25. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70. (Pubitemid 26419043)
26. Qin S, Seo JW, Zhang H, Qi J, Curry FR, Ferrara KW. An imaging-driven model for liposomal stability and circulation. Mol Pharm 2010;7:12-21.
27. Ponce AM, Viglianti BL, Yu DH, Yarmolenko PS, Michelich CR, Woo J, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007;99:53-63.
28. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008;60:1329-46.
29. Oku N. Delivery of contrast agents for positron emission tomography imaging by liposomes. Advanced Drug Delivery Rev 1999;37:53-61. (Pubitemid 29164499)
30. Phillips WT, Goins BA, Bao A. Radioactive liposomes. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2009; 1:69-83.
31. 99m to lipid vesicles containing the lipophilic chelate dipalmitoylphosphatidylethanolamine-DTTA. Int J Rad Appl Instrum B 1992;19:831-40.
32. Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int J Rad Appl Instrum B 1992;19:539-47.
33. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988;85:6949-53.
34. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-54. (Pubitemid 32183025)
35. Hwang KJ, Merriam JE, Beaumier PL, Luk KF. Encapsulation, with high efficiency, of radioactive metal ions in liposomes. Biochim Biophys Acta 1982;716:101-9. (Pubitemid 12057405)
36. 18F]FDP). Nucl Med Biol 2007;34:165-71.
37. 18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J Med Chem 2007;50:6454-7.
38. Mougin-Degraef M, Jestin E, Bruel D, Remaud-Le Saec P, Morandeau L, Faivre-Chauvet A, et al. High-activity radio-iodine labeling of conventional and stealth liposomes. J Liposome Res 2006; 16:91-102.
39. Awasthi V, Yee SH, Jerabek P, Goins B, Phillips WT. Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock. J Appl Physiol 2007;103:28-38. (Pubitemid 47092274)
40. 64Cu for positron emission tomography (PET) imaging. Bioconjugate Chem 2008;19:2577-84.
41. Paoli EE, Kruse DE, Seo JW, Zhang H, Kheirolomoom A, Watson KD, et al. An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation. J Control Release 2010;143:13-22.
42. Namba R, Maglione JE, Young LJT, Borowsky AD, Cardiff RD, MacLeod CL, et al. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol Cancer Res 2004;2:453-63. (Pubitemid 39121508)
43. Kostarelos K ED, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004;112:713-21. (Pubitemid 39425955)
44. Kostarelos K ED, Papakostas A, Yang WH, Ballangrud AM, Sgouros G. Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. J Liposome Res 2005;15: 15-27. (Pubitemid 40976304)
45. Eikenes L, Tari M, Tufto I, Bruland OS, de LangeDavies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer 2005;93:81-8. (Pubitemid 41078799)
46. Sedlacek HH, Seeman G, Hoffman D, Czech, Lorenz P, Kolar C, Bossler K. Antibodies as carriers of cytotoxicity. Contrib Oncol 1992; 43:74-5.